Salvia miltiorrhiza Bunge (Salvia miltiorrhiza), commonly referred to as Danshen, is a well-known herb in traditional Chinese medicine, the active ingredients of which are mostly categorized as water soluble and lipid soluble. Salvianolic acids are the major water-soluble phenolic acid constituents of Danshen; salvianolic acid B is the most prevalent, with salvianolic acid A (SAA) being the next most predominant form. SAA offers a wide array of pharmacological benefits, including cardiovascular protection, and anti-inflammatory, antioxidant, antiviral and anticancer activities. SAA is currently undergoing phase III clinical trials for diabetic peripheral neuropathy and has shown protective benefits against cardiovascular illnesses; furthermore, its safety and effectiveness are encouraging. By targeting several signaling pathways, preventing cell cycle progression, tumor cell migration, invasion and metastasis, normalizing the tumor vasculature and encouraging cell apoptosis, SAA can also prevent the growth of malignancies. In addition, it enhances sensitivity to chemotherapeutic drugs, and alleviates their toxicity and side effects. However, the broad therapeutic use of SAA has been somewhat limited by its low content in Salvia miltiorrhiza Bunge and the difficulty of its extraction techniques. Therefore, the present review focuses on the potential mechanisms of SAA in tumor prevention and treatment. With the anticipation that SAA will serve a notable role in clinical applications in the future, these discoveries may offer a scientific basis for the combination of SAA with conventional chemotherapeutic drugs in the treatment of cancer, and could establish a foundation for the development of SAA as an anticancer drug.
Salvia miltiorrhiza BungeSalvia miltiorrhizaSAAanticancer activitypro-apoptosisSichuan Science and Technology Program2022YFS06232024YFFK03462024NSFSC0561Sichuan Science and Technology Program Joint Innovation Grant2022YFS0623-B3Southwest Medical University Grant2021ZKZD005Sichuan Science and Technology Grant2020YFH0121Southwest Medical University College Student Innovation and Entrepreneurship Training Program2024314The present study was funded by the Sichuan Science and Technology Program (grant nos. 2022YFS0623, 2024YFFK0346 and 2024NSFSC0561), the Sichuan Science and Technology Program Joint Innovation Grant (grant no. 2022YFS0623-B3), the Southwest Medical University Grant (grant no. 2021ZKZD005), the Sichuan Science and Technology Grant (grant no. 2020YFH0121), and the Southwest Medical University College Student Innovation and Entrepreneurship Training Program (grant no. 2024314).Introduction
Global statistics indicate that there were ~20 million newly diagnosed cases of cancer and ~10 million cases of cancer-associated mortality in 2022 (1). Projections based on demographics indicate that the yearly incidence of new cancer cases might increase to 35 million by 2050, representing a 77% increase compared with 2022 (1). Current cancer treatments, including surgery, radiation and chemotherapy, have shown promising results; however, recurrence and metastasis due to chemotherapy resistance remain the leading causes of death in patients (2–4). Over the last few years, global interest in traditional Chinese medicine (TCM) as cancer treatment has rapidly increased (5–7). TCM is favored by an increasing number of patients due to its holistic approach and possibility for individualized treatment, as well as fewer side effects and its applicability to long-term treatment. TCM has become an indispensable part of comprehensive tumor therapy, and has been shown to aid the relief of symptoms and improve the quality of life of patients (8). The therapeutic effects of the active ingredients of TCM on malignant growth, including liver, lung and breast cancer growth, have been reported, providing new potential for cancer therapy (9–11). Furthermore, active ingredients of natural Chinese herbal medicines have extensive use in the treatment of cancer due to their high efficacy, lack of resistance, low toxicity and minimal side effects (12,13). It is anticipated that they may work around the disadvantages of currently available anticancer medications, and serve as adjuvants to chemotherapy by enhancing their effects and reducing toxicity. Consequently, they are gaining increasing attention in cancer prevention and treatment.
The present review focuses on the anticancer effects and mechanisms of the small molecule SAA from the traditional Chinese medicine Salvia miltiorrhiza Bunge (Salvia miltiorrhiza), also known as Danshen.
Source, structure and bioactivity of SAA
As a widely used traditional Chinese herb, Danshen contains various active ingredients that can be categorized into different groups according to their chemical and structural characteristics (14). These components are separated into two primary categories: Lipid-soluble tanshinones and water-soluble phenolic acids (15). Salvianolic acid and rosmarinic acid B make up the water-soluble phenolic acids, whereas the lipid-soluble tanshinones include tanshinone I and II, dihydrotanshinone I and cryptotanshinone (16). The salvianolic acids in Danshen include many compounds, namely salvianolic acids A-H, J-N, T/U and Y (17). Among these, SAA and salvianolic acid B are particularly regarded as having the highest antioxidant activity (18). Chemically, SAA is identified as (R)-3-(3,4-dihydroxyphenyl)-2-(((E)-3-(2- ((E)-3,4-dihydroxystyryl)-3,4-dihydroxyphenyl)acryloyl)oxy)propanoic acid, with a molecular formula of C26H22O10 (19,20). Structurally, SAA is a trimer consisting of danshensu and caffeic acid as its fundamental units. The molecular structure of SAA is depicted in Fig. 1 (21).
A principal water-soluble component of Salvia miltiorrhiza Bunge, salvianolic acid A (SAA), has been recognized for its pharmacological activities, including antioxidant (22), anti-inflammatory (23), antiviral (24), antitumor (25,26), vascular endothelial protective (27) and myocardial protective (28) properties.
Anticancer activity of SAA
The main water-soluble active ingredient in Danshen, SAA, influences cell migration, invasion, apoptosis and proliferation, all of which notably impact the occurrence and development of tumors (29,30). Unlike most chemotherapeutic drugs currently used in clinical settings, which typically target a single pathway and are susceptible to drug resistance (31), small-molecule components derived from natural products often exhibit antitumor effects by modulating multiple signaling pathways (32,33). For example, natural compounds can influence pathways that are critical for regulating tumor cell proliferation and growth, such as PI3K/Akt (34,35), Wnt/β-catenin (36–38) and NF-κB (39) pathways, thus providing a multifaceted approach to cancer treatment (40–42). In several tumor cells, including MCF-7 breast cancer cells, SCC-9 oral squamous cell carcinoma cells, and KG-1 and Kasumi-1 acute myeloid leukemia cells, SAA exerts its antitumor effects by inhibiting cell invasion, migration and proliferation, and promotes apoptosis by targeting different signaling pathways, including the PI3K/Akt, Raf/extracellular signal-regulated kinase (ERK) kinase (MEK) and mammalian target of rapamycin (mTOR) pathways (43–45). Through its electrophilic α,β-unsaturated ester moiety, SAA functions as a covalent ligand to alter biological proteins (46). The protein targets of SAA have been identified using chemoproteomics and phosphoproteomics (47). According to chemoproteomics analysis, SAA covalently alters a minimum of 46 proteins, including the mTOR complex 1 (mTORC1) subunit Raptor to inhibit mTORC1 (47). According to the phosphoproteomics profile, SAA primarily interferes with the PI3K/Akt/mTOR signaling pathway (47). SAA exhibits multifaceted antitumour properties. These include the regulation of intracellular energy dynamics [e.g., induction of endogenous apoptosis (48) and suppression of mitochondrial membrane potential (49)], inhibition of tumour cell proliferation (50), suppression of tumour cell migratory and invasive (51), enhancement of chemotherapy sensitivity (49,52) or reversal of chemotherapy resistance (53), inhibition of tumour angiogenesis (54) and modulation of genomic instability and mutations (55) (Fig. 2).
Anticancer mechanism of SAA
Research has indicated that the anticancer effect of SAA is multifaceted and involves several molecular mechanisms. A key aspect is activation of the caspase family, which is crucial for the execution of apoptosis (48). In addition, the levels of proteins that inhibit apoptosis have been shown to be decreased by SAA, such as those of anti-apoptotic Bcl-2, while pro-apoptotic proteins such as Bak and Bax are simultaneously activated (49). Furthermore, SAA may inhibit the c-mesenchymal-to-epithelial transition factor (c-MET) and reduce the activity of matrix metalloproteinases (MMPs), such as MMP-2 and MMP-9, which are implicated in tumor invasion and metastasis (50,51). In a previous study, SAA has been shown to decrease the expression of drug-resistant proteins, specifically P-glycoprotein and multidrug resistance-1 (MDR1) (43). Finally, SAA has been found to regulate critical signaling pathways, including PI3K/Akt/MAPK and c-Raf/MEK/ERK pathways, which are essential for cell survival and proliferation.
Regulation of tumor cell apoptosis by SAA
The process through which a cell stops growing and dividing, and enters a phase that eventually leads to regulated cell death, is called apoptosis or programmed cell death (56). The impairment of a series of processes in cell apoptosis, as well as defects in death receptor signaling, impacts the growth of tumor cells (57,58). Notably, promoting cancer cell apoptosis is a strategy for treating tumors, whereas inhibiting apoptosis or other cell death mechanisms can directly impact tumor cell sensitivity to chemotherapy (56,59).
Two mechanisms underlie apoptosis: The intrinsic mechanism, which depends on mitochondrial components, and the extrinsic mechanism, which is regulated by death receptors (56,60,61). A key event in intrinsic apoptosis is the release of cytochrome c (Cyto C) from the mitochondria, which is regulated by the Bcl-2 family (62). This family consists of anti-apoptotic proteins, such as Bcl-2 and Bcl-xl, as well as pro-apoptotic proteins, such as Bax, Bad, Bim and Bid. Bax forms oligomers on the mitochondrial outer membrane, promoting Cyto C release (61); this activates the caspase family, which is split into initiators such as caspases 8, 9 and 10, and effectors such as caspases 3, 6 and 7 (63). Caspase 9 and apoptotic peptidase activating factor 1 form apoptotic bodies, activating caspase 3 to induce apoptosis (64). By contrast, Bcl-2 inhibits apoptosis by sequestering Bax and preventing Cyto C release (65–68). After treating esophageal cancer cells with SAA, caspase 9, a protease that causes DNA fragmentation, receives an upstream apoptosis signal and activates downstream caspase 3, leading to apoptosis (69). After treating the esophageal cancer cell line KYSE-150 with SAA, while Bcl-2 expression levels were much lower, those of Bax, as well as cleaved-caspase 9 and 3, were substantially greater (48). By upregulating Bak and downregulating Bcl-xl, SAA therapy causes KG-1, THP-1 and Kasumi-1 acute myeloid leukemia cells to undergo apoptosis through the intrinsic apoptotic pathway. Subsequently, poly ADP-ribose polymerase is cleaved, which activates caspase 3 (Fig. 3) (45). In doxorubicin hydrochloride (DOX)-resistant breast cancer cells (MCF-7/MDR), SAA causes intrinsic apoptosis by caspase activation, Bax upregulation, Bcl-2 downregulation and a decrease in mitochondrial membrane potential (49). Furthermore, SAA treatment enhances Bax and decreases Bcl-2 expression in KYSE-150 esophageal cancer cells, thereby inducing apoptosis (48). The aforementioned mechanisms likely involve the inhibition of c-MET gene transcription and protein expression in HepG-2 liver cancer cells, which in turn reduces the degree of Akt phosphorylation in the downstream PI3K/Akt signaling cascade (70) (Table I). These studies have suggested that SAA mediates the intrinsic apoptotic pathway in various tumor cells; however, whether SAA induces apoptosis via an extrinsic pathway has not yet been reported, to the best of our knowledge.
SAA inhibits tumor cell proliferation
Tumor cells exhibit the hallmark characteristic of unlimited proliferation. Capitalizing on this advantage, they not only evade growth-inhibitory signals but also resist cell death, often through the loss of tumor suppressor gene function (71). Phosphatase and tensin homolog (PTEN) is a widely studied gene that suppresses tumor growth and encodes a phosphatase that dephosphorylates phosphatidylinositol (3,4,5)-trisphosphate, leading to the inactivation of downstream effectors, particularly Akt (72). Essential for regulating various biological functions, the PI3K/Akt signaling pathway is particularly important for cell cycle progression, cell proliferation and apoptosis prevention. This signaling cascade is frequently found to be disrupted in cancer (73–75). By reducing the expression of PI3K and Akt, cell cycle arrest and effective inhibition of tumor cell growth can be accomplished (76). Treatment of A549 lung cancer cells with different concentrations of SAA (10, 20 and 30 µg/ml) for different durations (6, 12 and 24 h) has been shown to significantly increase PTEN protein expression levels and consistently reduce AKTS473 phosphorylation (Fig. 3). These findings indicate how suppressing tumor cell proliferation and encouraging apoptosis have concentration- and time-dependent effects (77).
Endothelin-1, a small vasoactive peptide that is upregulated in the plasma and tissue specimens of various patients with solid tumors, can activate endothelin A receptor (ETAR) and endothelin B receptor through autocrine and paracrine interaction, thereby regulating the proliferation of tumor cells (78). SAA, an ETAR antagonist, significantly inhibits spontaneous tumor cell proliferation and exhibits concentration-dependent effects (79). Furthermore, SAA and oxymatrine together have been reported to exert a synergistic impact on immortalized H8 cervical epithelial cells in a study of precancerous lesions in cervical cancer (80). This combination effectively halts the cell cycle in the G2/M phase in H8 cells, thereby suppressing proliferation (80). In vitro experiments have revealed that SAA suppresses diffuse large B-cell lymphoma (DLBCL) proliferation though regulating the MAPK signaling pathway; specifically, SAA upregulates c-Jun N-terminal kinase, and downregulates phosphorylated (p-)ERK and p-p38 MAPK (81). In vivo studies employing xenograft mouse models have supported these findings, further confirming that SAA can suppress the tumor growth of DLBCL OCI-Ly01 and SUDHL-8 cells (81). In addition, the intermediate metabolite of SAA, S-3-1, inhibits the spread of various types of cancer, including small cell lung cancer, lung adenocarcinoma, oral squamous cell carcinoma, colon cancer, gastric cancer and pancreatic cancer (82). The cell cycle is arrested at the G2/M phase by SAA, which can also dose-dependently reduce the proliferation of the human melanoma A2058 and A375 cell lines. Notably, SAA causes checkpoint kinase (Chk)-2 phosphorylation to be selectively induced without impacting Chk-1; this results in the degradation of the genes cell division cycle (CDC)25A and CDC2, which are controlled by Chk-2, but has no effect on the Chk1-CDC25C axis (29).
SAA inhibits the migration and invasion of tumor cells
One major factor in cancer-associated mortality is tumor metastasis, which is a complex and multidimensional process (83). This progression is marked by genetically unstable cancer cells that adapt to and thrive within tissue microenvironments distant from the primary tumor site (84). When cells with the ability to metastasize invade new tissues, they undergo a selection process that favors traits for survival and proliferation (85). Concurrently, recruitment of a distinctive tumor stroma occurs, which serves a vital role in facilitating the invasion and establishment of metastatic cells in distant organs (86). A mechanism known as epithelial-mesenchymal transition (EMT) causes epithelial cancer cells to change from their standard epithelial phenotype to a mesenchymal phenotype. Cancer cells that undergo EMT exhibit a greater ability to migrate and invade, making them more likely to metastasize (87). EMT is a pivotal step towards invasiveness, orchestrated by many cell adhesion molecules and intermediate filaments, including E-cadherin, N-cadherin and vimentin (88–90).
MMPs are responsible for degrading the components of the basement membrane and the extracellular matrix (91). Through interactions with a series of cell adhesion molecules, they participate in altering the adhesive properties between tumor cells and their environment, facilitating the movement of tumor cells through the extracellular matrix (92). Therefore, MMPs such as MMP-2 and MMP-9 are required for cancer cell metastasis (93–95). Targeting these crucial mediators of metastasis can aid in inhibiting cancer cell migration and invasion. SAA has been reported to reduce MMP-2 expression in SCC-9 oral squamous cell carcinoma cells through the Raf/MEK/ERK pathway to regulate cell migration (44). Similarly, SAA treatment can inhibit MMP-2 protein expression and activity in HONE-1 and NPC-39 nasopharyngeal carcinoma cells in a concentration-dependent manner, preventing migration and invasion (96). SAA also inhibits MCF-7 cell migration and invasion by preventing EMT, leading to higher E-cadherin expression, and reduced vimentin and N-cadherin levels (30). Previous studies have indicated that SAA inhibits cancer metastasis by regulating MMP-2 levels and important EMT markers, such as E-cadherin, vimentin and N-cadherin; however, further research is required to ascertain whether SAA can also impede tumor migration and invasion through the modulation of additional EMT markers, such as zinc finger e-box binding homeobox 1, snail family transcriptional repressor (Snail) 1, Snail 2, twist family bHLH transcription factor 1 and fibronectin.
SAA promotes chemotherapy sensitization and reverses chemotherapy resistance
Resistance to chemotherapeutic drugs poses a notable challenge for cancer therapy (97); therefore, it is essential to overcome tumor resistance and enhance tumor cell sensitivity to these drugs (98). c-MET is a receptor tyrosine kinase that becomes activated upon binding to its ligand, hepatocyte growth factor (HGF) (48). The HGF/c-MET axis is frequently abnormally activated in gastric (99), lung (100) and pancreatic (101) cancer. This abnormal activation is often associated with c-MET gene mutations, overexpression of the c-MET protein and gene amplification (102). The activation of several downstream signaling pathways, including PI3K/Akt, Ras/MAPK, JAK/STAT, SRC and Wnt/β-catenin, can drive tumor progression and enhance the resistance of tumor cells to therapeutic agents (103–105). Thus, c-MET could potentially serve as a crucial target for overcoming tumor cell resistance. Drugs or small molecules that target c-MET can help overcome chemotherapy resistance in tumor cells (106).
SAA is capable of partially reversing cisplatin resistance in A549/DDP lung cancer cells by blocking the c-MET/Akt/mTOR signaling axis (50). SAA has been shown to downregulate MDR1 in A549 cells, while simultaneously upregulating the expression of microRNAs (miRNAs) associated with this gene. This dual action suggests that SAA may influence MDR1 expression by regulating tumor cell miRNAs. Consequently, this regulatory mechanism could potentially lead to the reversal of multidrug resistance in A549 cells (107). Furthermore, SAA may reverse drug resistance in lung cancer cells through regulation of the PI3K/Akt signaling pathway (108). In MCF-7 breast cancer cells, SAA decreases transgelin 2 (TAGLN2) and Bcl-2 levels, and increases levels of PTEN, Bax, cleaved-PAPR, cleaved-caspase 3 and cleaved-caspase 9. SAA enhances MCF-7 breast cancer cell sensitivity to paclitaxel by inhibiting the PI3K/Akt signaling pathway and activating the mitochondrial apoptosis pathway (43,49). Furthermore, SAA can suppress the migration and invasion of paclitaxel-resistant MCF-7 breast cancer cells by downregulating TAGLN2 expression, thereby reversing paclitaxel resistance in these cells (30). Furthermore, by blocking the TAGLN2/PI3K/Akt signaling pathway, SAA can inhibit the malignant growth of U87 glioma cells and increase their susceptibility to temozolomide; therefore, SAA could potentially serve as an adjunctive medication in clinical chemotherapy for glioma cells (109). In adriamycin-resistant MCF-7 breast cancer cells, protein arginine methyltransferase 1 (PRMT1) potentially contributes to the upregulation of MDR1, which is activated by the pregnane X receptor (PXR). In addition, a PRMT inhibitor may suppress MDR1 by interfering with the PRMT1 and PXR interaction. Notably, SAA can act as a PRMT1 inhibitor to increase the anticancer effects of DOX by increasing the sensitivity of drug-resistant breast cancer cells to it (52). A previous study indicated that, compared with the use of DOX alone, SAA alone or the SAA/DOX combination, E-[c(RGDfK)2]/folic acid (FA) co-modification of nanostructured lipid carriers (NLC) in conjunction with SAA and DOX exhibit the most effective antitumor activity. These findings suggested that SAA and DOX may have a synergistic effect in breast cancer treatment (53). Furthermore, the renal toxicity levels of E-[c(RGDfK)2]/FA-NLC-SAA/DOX were revealed to be low, with no abnormalities observed in the ex vivo kidney pathology examination at the end of the study. In addition, SAA is capable of antagonizing the nephrotoxic effects of DOX, highlighting its significant potential in enhancing the tolerance of cancer patients to chemotherapy (110).
SAA is involved in tumor angiogenesis
Angiogenesis is the process through which endothelial cells migrate and proliferate within preexisting small blood vessels, or venules, to produce new blood vessels, mostly capillaries (111). For tumors, this mechanism is essential, as it provides the oxygen and nutrients needed for development and spread (112). Furthermore, the blood circulation makes it easier for tumor cells to spread to different areas of the body (113). As a result, most cancers promote tumor angiogenesis, the process through which new capillaries grow in the surrounding tissue. Notably, not all cancers depend on the development of new blood vessels, as some can endure and proliferate by altering their metabolism (114,115). Therefore, inhibiting capillary formation during tumor treatment can indirectly block the development and metastasis of tumor cells (116). When it comes to inhibiting tumor-secreted glucose-regulated protein 78 (GRP78) in DLD1 and HCT-116 colon cancer cells, SAA has been shown to be the most successful among Diosmin, Quertruicin, Vitexin, Baicain, SAA, Isovitexin, Narigin and Platycodin D; SAA can encourage the breakdown of GRP78 through the lysosomal pathway and prevent its release into the tumor microenvironment (54). Furthermore, SAA has been shown to specifically interact with GRP78 and inhibit tumor angiogenesis (54). DOX, as one of the anthracycline antibiotics, is extensively used in cancer therapy (117). In a mouse lung cancer model, it has been demonstrated that SAA is able to normalize the tumor vasculature by targeting PKM2. This focused strategy affects alterations to the shape and function of the tumor vasculature, enabling the effective delivery of DOX and thereby enhancing its therapeutic efficacy. Concurrently, SAA is capable of reducing the cardiotoxicity caused by DOX (118).
Additional anticancer effects of SAA
Nucleotide biosynthesis involves two pathways: De novo and salvage synthesis. Given the elevated nucleoside transport activity in tumor cells, targeting nucleoside transport provides a potential opportunity for combating cancer (119). SAA inhibits nucleoside transport activity in murine Ehrlich ascites carcinoma cells, and it enhances the antitumor effects of chemotherapeutic drugs, such as 5-fluorouracil, on KB human oral squamous cell carcinoma cells (55). Therefore, combining SAA with chemotherapeutic drugs may be promising for improving the efficiency of cancer treatment (55). Furthermore, SAA can exert antitumor effects in the Paca human pancreatic cancer cell line by enhancing gap junctional intercellular communication and inhibiting RAS function (82). In a previous study, E-[c(RGDfK)2]/FA-modified NLCs were co-loaded with DOX and SAA to create E-[c(RGDfK)2]/FA-NLC-SAA/DOX; this multipurpose drug delivery system based on nanotechnology is distinguished by its high encapsulation efficiency and compact size. In the 4T1 animal tumor model, this formulation was able to markedly increase the antitumor actions of SAA/DOX by encouraging tumor cell death and inhibiting cell proliferation (107). To the best of our knowledge, this was the first study to show that SAA alone inhibits the polarization of macrophages into M2-like tumor-associated macrophages (TAMs) by suppressing the ERK pathway and promoting the re-polarization of M2-like TAMs into M1-like TAMs; this modulation of M1/M2 TAM polarization may underlie the antitumor effects of SAA (120).
The expression levels of two well-known hypoxia indicators, hypoxia-inducible factor 1α and carbonic anhydrase IX (121,122), have been shown to be significantly reduced in mouse Lewis lung carcinoma cells LLC and mouse melanoma high metastatic cells B16F10 following SAA treatment. These findings suggested that SAA may have a marked impact in lowering tumor hypoxia (118). Furthermore, the lactate levels in LLC and B16F10 tumors from an SAA-treated group have been shown to be significantly reduced compared with those in a vehicle control group (118). These findings collectively suggested that SAA could be essential in reducing tumor growth by improving the hypoxic microenvironment (118). Through a caveolae-dependent mechanism, SAA has been reported to increase the transcellular permeability of the tumor blood-brain barrier while decreasing its paracellular permeability; this can enhance the ability of DOX to treat HCMEC/D3 immortalized human cerebral microvascular endothelial cells and make it easier for the drug to enter brain tumor tissues. Thus, SAA and DOX together might provide a new method of treating glioma cells (123). In conclusion, SAA has shown considerable promise as a drug monomer. Preclinical and experimental studies have demonstrated its potential to enhance the efficacy of antitumor drugs, providing new possibilities for cancer treatment. The unique mechanism of action of SAA makes it a strong candidate as an effective adjunctive antitumor agent, offering new perspectives for future therapeutic strategies.
Conclusions and perspectives
Chinese medicine has garnered notable attention from experts and scholars, both domestically and internationally, due to its distinctive characteristics and advantages in treating tumors. Notably, it operates through multiple targets, effects and pathways, contributing to its precise efficacy. Chinese medicine is also widely available and well known for having few adverse effects and low toxicity, which makes it a good substitute in oncology.
Research on drug delivery carriers has advanced, particularly in the domain of specialized delivery systems. These systems have attracted considerable attention due to their enhanced in vivo stability, improved bioavailability, increased drug efficacy, enhanced tissue targeting, reduced off-target adverse reactions and ability to co-deliver drugs. For example, research has shown that specific ligands, such as E-[c(RGDfK)2]/FA, can effectively deliver drugs to target tissues, thereby enhancing the therapeutic effects of the drugs (110).
In the field of TCM, as research into active ingredients develops, it has been shown that terpenoids, alkaloids, flavonoids, quinones, polysaccharides and other active ingredients of TCM not only possess notable pharmacological activity but also show potential as drug delivery nanocarriers (124). SAA, as a type of salvianolic acid, is also seen as a promising candidate in drug delivery systems; however, the extraction methods for SAA have certain shortcomings (125). By developing new extraction technologies and optimizing extraction conditions, its extraction efficiency and safety can be improved. In practice, the use of nanoparticles for targeted medication delivery can minimize side effects, improve therapeutic benefits and decrease toxicity, in addition to increasing the effectiveness of SAA.
Notably, E-[c(RGDfK)2]/FA-NLC-SAA/DOX exhibits low renal toxicity, as no abnormalities have been found in ex vivo kidney pathology examinations. SAA is also capable of antagonizing the nephrotoxic effects of DOX, further demonstrating its low toxicity and lack of side effects (107). The pharmacological mechanisms of SAA must be thoroughly studied to support widespread therapeutic application. Currently, most studies on the use of SAA for tumor treatment are in the preliminary stages, and many of the underlying mechanisms of action have yet to be fully elucidated. A comprehensive awareness of the antitumor mechanisms of SAA is crucial for advancing TCM and improving tumor treatment strategies.
Clinical trials of SAA have shown promise in the fields of diabetic microangiopathy (CTR20210544) and acute myocardial infarction (CTR20213269) (126). The clinical trial for diabetic microangiopathy has progressed to phase III. The results of the phase II trial (CTR20210544) have indicated that SAA tablets are effective in alleviating the symptoms of diabetic peripheral neuropathy, such as limb numbness and tingling, with good safety. However, the current trials are subject to certain limitations, such as strict inclusion and exclusion criteria (e.g., excluding patients with severe cardiovascular and cerebrovascular diseases, or abnormal liver and kidney function), which may restrict its application in a broader population. In the field of acute myocardial infarction, the phase II clinical trial (CTR20213269) of Salvianolic acid A sodium salt monohydrate for injection is ongoing, aiming to assess its efficacy and safety in myocardial protection after percutaneous coronary intervention. The trial, which follows a randomized, double-blind, placebo-controlled and multicenter design, has shown that SAA sodium has potential advantages in suppressing inflammatory responses and reducing myocardial injury. However, the trial also had strict participant selection criteria, such as excluding patients with severe liver and kidney dysfunction, a history of malignant tumors or allergies to other drugs, which may affect its clinical promotion. Future research should focus on expanding the sample size, extending the trial duration and further exploring the mechanism of action of SAA to better advance its clinical application.
Acknowledgements
Not applicable.
Availability of data and materials
Not applicable.
Authors' contributions
CXL and WLY conceptualized the review and wrote the original draft. CXL, QX, STJ, DL, CT and WLY reviewed and edited the review, and were involved in visualization. WLY was responsible for supervision, project administration and funding acquisition. Data authentication is not applicable. All authors have read and approved the final version of the manuscript.
Ethics approval and consent to participate
Not applicable.
Patient consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
AbbreviationsmTOR
mammalian target of rapamycin
c-MET
mesenchymal-to-epithelial transition factor
MDR1
multidrug resistance-1
Cyto C
cytochrome c
PTEN
phosphatase and tensin homolog
ETAR
endothelin A receptor
DLBCL
diffuse large B-cell lymphoma
p-
phosphorylated
Chk-2
checkpoint kinase-2
EMT
epithelial-mesenchymal transition
HGF
hepatocyte growth factor
PRMT1
protein arginine methyltransferase 1
PXR
pregnane X receptor
GRP78
glucose-regulated protein 78
DOX
doxorubicin hydrochloride
TAMs
tumor-associated macrophages
FA
folic acid
TCM
traditional Chinese medicine
SAA
salvianolic acid A
ReferencesBrayFLaversanneMSungHFerlayJSiegelRLSoerjomataramIJemalAGlobal cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesCA Cancer J Clin74229263202410.3322/caac.2183438572751Organization GWHGlobal Breast Cancer Initiative Implementation Framework: Assessing, strengthening and scaling-up of services for the early detection and management of breast cancerCC BY-NC-SA 3.0 IGO2023XinJSongMLiuXZouHWangJXiaoLJiaYZhangGJiangWLeiMA new strategy of using low-dose caffeic acid carbon nanodots for high resistance to poorly differentiated human papillary thyroid cancerJ Nanobiotechnology22571202410.1186/s12951-024-02792-y39294724DiefenhardtMMartinDHofheinzRDGhadimiMFokasERödelCFleischmannMPersistent lymph node metastases after neoadjuvant chemoradiotherapy for rectal cancerJAMA Netw Open7e2432927202410.1001/jamanetworkopen.2024.3292739264626GuoJChenXWuMWangDZhaoYLiQTangGCheFXiaZLiangZTraditional Chinese medicine FYTF-919 (Zhongfeng Xingnao oral prescription) for the treatment of acute intracerebral haemorrhage: A multicentre, randomised, placebo-controlled, double-blind, clinical trialLancet40421872196202410.1016/S0140-6736(24)02261-X39547249HuangWWangJKuangMXiaoZFanBSunGTanZExploring global research status and trends in anti-obesity effects of traditional Chinese medicine through intestinal microbiota: A bibliometric studyFront Cell Infect Microbiol131271473202310.3389/fcimb.2023.127147338045760FanYLiuJMiaoJZhangXYanYBaiLChangJWangYWangLBianYZhouHAnti-inflammatory activity of the Tongmai Yangxin pill in the treatment of coronary heart disease is associated with estrogen receptor and NF-κB signaling pathwayJ Ethnopharmacol276114106202110.1016/j.jep.2021.11410633838287LiuYFangCLuoJGongCWangLZhuSTraditional Chinese medicine for cancer treatmentAm J Chin Med52583604202410.1142/S0192415X2450025338716616LiJWangSWangNZhengYYangBWangXZhangJPanBWangZAiduqing formula inhibits breast cancer metastasis by suppressing TAM/CXCL1-induced Treg differentiation and infiltrationCell Commun Signal1989202110.1186/s12964-021-00802-234461944YanXYaoCFangCHanMGongCHuDShenWWangLLiSZhuSRocaglamide promotes the infiltration and antitumor immunity of NK cells by activating cGAS-STING signaling in non-small cell lung cancerInt J Biol Sci18585598202210.7150/ijbs.6501935002511ManSLiuWBiJBaiJWuQHuBHuJMaLSmart mesoporous silica nanoparticles loading curcumin inhibit liver cancerJ Agric Food Chem722574325754202410.1021/acs.jafc.4c0820239506560IslamMSWangCZhengJPaudyalNZhuYSunHThe potential role of tubeimosides in cancer prevention and treatmentEur J Med Chem162109121201910.1016/j.ejmech.2018.11.00130439592MaJWangJWanYWangSJiangCProbiotic-fermented traditional Chinese herbal medicine, a promising approach to maintaining the intestinal microecologyJ Ethnopharmacol337118815202410.1016/j.jep.2024.11881539270882ZhouLZuoZChowMSDanshen: An overview of its chemistry, pharmacology, pharmacokinetics, and clinical useJ Clin Pharmacol4513451359200510.1177/009127000528263016291709JiaYYaoDBiHDuanJLiangWJingZLiuMSalvia miltiorrhiza Bunge (Danshen) based nano-delivery systems for anticancer therapeuticsPhytomedicine128155521202410.1016/j.phymed.2024.15552138489891HuangJZhangJSunCYangRShengMHuJKaiGHanBAdjuvant role of Salvia miltiorrhiza bunge in cancer chemotherapy: A review of its bioactive components, health-promotion effect and mechanismsJ Ethnopharmacol318117022202410.1016/j.jep.2023.11702237572929ShanXXHongBZLiuJWangGKChenWDYuNJPengDYWangLZhangCYReview of chemical composition, pharmacological effects, and clinical application of Salviae Miltiorrhizae Radix et Rhizoma and prediction of its Q-markersZhongguo Zhong Yao Za Zhi46549655112021(In Chinese)34951201ZhangJJinQDengYHouJWuWGuoDNew depsides from the roots of Salvia miltiorrhiza and their radical-scavenging capacity and protective effects against H2O2-induced H9c2 cellsFitoterapia1214652201710.1016/j.fitote.2017.06.01828647481National Center for Biotechnology Information‘PubChem Compound Summary for CID 5281793Salvianolic acid A’ PubChemhttps://pubchem.ncbi.nlm.nih.gov/compound/Salvianolic-acid-A2January2024ZhaoHHanBLiXSunCZhaiYLiMJiangMZhangWLiangYKaiGSalvia miltiorrhiza in breast cancer treatment: A review of its phytochemistry, derivatives, nanoparticles, and potential mechanismsFront Pharmacol13872085202210.3389/fphar.2022.87208535600860KimSChenJChengTGindulyteAHeJHeSLiQShoemakerBAThiessenPAYuBPubChem 2023 updateNucleic Acids Res51D1373D1380202210.1093/nar/gkac95636305812DiaoHYZhuWLiuJYinSWangJHLiCLSalvianolic acid a improves rat kidney injury by regulating MAPKs and TGF-β1/Smads signaling pathwaysMolecules283630202310.3390/molecules2808363037110864ZhangHFWangYLGaoCGuYTHuangJWangJHWangJHZhangZSalvianolic acid A attenuates kidney injury and inflammation by inhibiting NF-κB and p38 MAPK signaling pathways in 5/6 nephrectomized ratsActa Pharmacol Sin3918551864201810.1038/s41401-018-0026-629795135ChenZLiDWangTLiYQinPZhuHZhangMLiWYuLDuanHSalvianolic acid A inhibits pseudorabies virus infection by directly inactivating the virus particlePhytomedicine134156015202410.1016/j.phymed.2024.15601539244942MeirellesLEFSouzaMVFCarobeliLRMorelliFMariNLDamkeEShinobu MesquitaCSTeixeiraJJVConsolaroMELSilvaVRSDCombination of conventional drugs with biocompounds derived from cinnamic acid: A promising option for breast cancer therapyBiomedicines11275202310.3390/biomedicines1102027536830811JiangHWangSLiuYZhengCChenLZhengKXuZDaiYJinHChengZTargeting EFNA1 suppresses tumor progression via the cMYC-modulated cell cycle and autophagy in esophageal squamous cell carcinomaDiscov Oncol1464202310.1007/s12672-023-00664-937160815YangLLLiDYZhangYBZhuMYChenDXuTDSalvianolic acid A inhibits angiotensin II-induced proliferation of human umbilical vein endothelial cells by attenuating the production of ROSActa Pharmacol Sin334148201210.1038/aps.2011.13322101169ZhongWSunBGaoWQinYZhangHHuaiLTangYLiangYHeLZhangXSalvianolic acid A targeting the transgelin-actin complex to enhance vasoconstrictionEBioMedicine37246258201810.1016/j.ebiom.2018.10.04130361065PuXYMeiYZhengQKoCYInhibition of melanoma cell growth by salvianolic acid A through CHK2-CDC25A pathway modulationFront Biosci (Landmark Ed)29213202410.31083/j.fbl290621338940031ZhengXChenSYangQCaiJZhangWYouHXingJDongYSalvianolic acid A reverses the paclitaxel resistance and inhibits the migration and invasion abilities of human breast cancer cells by inactivating transgelin 2Cancer Biol Ther1614071414201510.1080/15384047.2015.107099026176734QinXGuoJLiHHeHCaiFChenXChenMChenTMaLSelenium electrophilic center responsive to biological electron donors for efficient chemotherapyAdv Sci (Weinh)e2412062202510.1002/advs.20241206239950936ZhaoMJiangXFangJLinYLiYPeiRYePLuYJiangLThe kava chalcone flavokawain B exerts inhibitory activity and synergizes with BCL-2 inhibition in malignant B-cell lymphomaPhytomedicine120155074202310.1016/j.phymed.2023.15507437716033HseuYCHuangYCThiyagarajanVMathewDCLinKYChenSCLiuJYHsuLSLiMLYangHLAnticancer activities of chalcone flavokawain B from Alpinia pricei Hayata in human lung adenocarcinoma (A549) cells via induction of reactive oxygen species-mediated apoptotic and autophagic cell deathJ Cell Physiol2341751417526201910.1002/jcp.2837530847898ZhangWDongJXuJQianYChenDFanZYangHXiangJXueXLuoXColumbianadin suppresses glioblastoma progression by inhibiting the PI3K-Akt signaling pathwayBiochem Pharmacol223116112202410.1016/j.bcp.2024.11611238458331JiangSWangPSunXZhangMZhangSCaoYWangYLiuLGaoXMechanistic study of leukopenia treatment by Qijiao shengbai Capsule via the Bcl2/Bax/CASAPSE3 pathwayFront Pharmacol151451553202410.3389/fphar.2024.145155339295929YeCYaoZWangYZhangCAsiaticoside promoted ferroptosis and suppressed immune escape in gastric cancer cells by downregulating the Wnt/β-catenin pathwayInt Immunopharmacol134112175202410.1016/j.intimp.2024.11217538733821ShinNLeeHJSimDYAhnCHParkSYKohWKohJKohBSKohBKohSHAnti-warburg mechanism of ginsenoside F2 in human cervical cancer cells via activation of miR193a-5p and inhibition of β-Catenin/c-Myc/hexokinase 2 signaling axisInt J Mol Sci259418202410.3390/ijms2517941839273365NilkhetSVongthipWLertpatipanpongPPrasansuklabATencomnaoTChuchawankulSBaekSJErgosterol inhibits the proliferation of breast cancer cells by suppressing AKT/GSK-3beta/beta-catenin pathwaySci Rep1419664202410.1038/s41598-024-70516-139179606PanCXuYJiangZFanCChiZZhangYMiaoMRenYWuZXuLNaringenin relieves paclitaxel-induced pain by suppressing calcitonin gene-related peptide signalling and enhances the anti-tumour action of paclitaxelBr J Pharmacol1831363159202410.1111/bph.1639738715438LinWSLelandJVHoCTPanMHOccurrence, bioavailability, anti-inflammatory, and anticancer effects of pterostilbeneJ Agric Food Chem681278812799202010.1021/acs.jafc.9b0786032064876LiYXuCWengWGoelACombined treatment with Aronia berry extract and oligomeric proanthocyanidins exhibit a synergistic anticancer efficacy through LMNB1-AKT signaling pathways in colorectal cancerMol Carcinog6321452157202410.1002/mc.2380039282961SzokaLStockiMIsidorovVDammarane-Type 3,4-seco-triterpenoid from silver birch (Betula pendula Roth) buds induces melanoma cell death by promotion of apoptosis and autophagyMolecules294091202410.3390/molecules2917409139274939CaiJChenSZhangWZhengXHuSPangCLuJXingJDongYSalvianolic acid A reverses paclitaxel resistance in human breast cancer MCF-7 cells via targeting the expression of transgelin 2 and attenuating PI3 K/Akt pathwayPhytomedicine2117251732201410.1016/j.phymed.2014.02.01225442283FangCYWuCZChenPNChangYCChuangCYLaiCTYangSFTsaiLLAntimetastatic potentials of salvianolic acid A on oral squamous cell carcinoma by targeting MMP-2 and the c-Raf/MEK/ERK pathwayEnviron Toxicol33545554201810.1002/tox.2254229385302PeiRSiTLuYZhouJXJiangLSalvianolic acid A, a novel PI3K/Akt inhibitor, induces cell apoptosis and suppresses tumor growth in acute myeloid leukemiaLeuk Lymphoma5919591967201810.1080/10428194.2017.139931429164984PéczkaNOrgovánZÁbrányi-BaloghPKeserűGMElectrophilic warheads in covalent drug discovery: An overviewExpert Opin Drug Discov17413422202210.1080/17460441.2022.203478335129005ZhengMZhangYXuYHanYWuYKangJChemoproteomics and phosphoproteomics profiling reveals salvianolic acid a as a covalent inhibitor of mTORC1J Proteome Res2224502459202310.1021/acs.jproteome.3c0018837347238YinXFengYKangWEffect of salvianolic acid A on the proliferation and apoptosis in esophageal cancer cells and the underlying mechanismsZhong Nan Da Xue Xue Bao Yi Xue Ban45126912752020(In English, Chinese)35753740WangXWangCZhangLLiYWangSWangJYuanCNiuJWangCLuGSalvianolic acid A shows selective cytotoxicity against multidrug-resistant MCF-7 breast cancer cellsAnticancer Drugs26210223201510.1097/CAD.000000000000018425419632TangXLYanLZhuLJiaoDMChenJChenQYSalvianolic acid A reverses cisplatin resistance in lung cancer A549 cells by targeting c-met and attenuating Akt/mTOR pathwayJ Pharmacol Sci13517201710.1016/j.jphs.2017.06.00628939129ZhangTXuJLiDChenJShenXXuFTengFDengYMaHZhangLSalvianolic acid A, a matrix metalloproteinase-9 inhibitor of Salvia miltiorrhiza, attenuates aortic aneurysm formation in apolipoprotein E-deficient micePhytomedicine2111371145201410.1016/j.phymed.2014.05.00324916705LiTKongANMaZLiuHLiuPXiaoYJiangXWangLProtein arginine methyltransferase 1 may be involved in pregnane × receptor-activated overexpression of multidrug resistance 1 gene during acquired multidrug resistantOncotarget72023620248201610.18632/oncotarget.775226934120KebebeDWuYZhangBYangJLiuYLiXMaZLuPLiuZLiJDimeric c(RGD) peptide conjugated nanostructured lipid carriers for efficient delivery of Gambogic acid to breast cancerInt J Nanomedicine1461796195201910.2147/IJN.S20242431447559YangYZhangLLaXLiZLiHGuoSSalvianolic acid A inhibits tumor-associated angiogenesis by blocking GRP78 secretionNaunyn Schmiedebergs Arch Pharmacol392467480201910.1007/s00210-018-1585-230560355ZhangSHSuJZhenYSSalvianolic acid A inhibits nucleoside transport and potentiates the antitumor activity of chemotherapeutic drugsYao Xue Xue Bao394964992004(In Chinese)15493835D'ArcyMSCell death: A review of the major forms of apoptosis, necrosis and autophagyCell Biol Int43582592201910.1002/cbin.1113730958602WongRSApoptosis in cancer: From pathogenesis to treatmentJ Exp Clin Cancer Res3087201110.1186/1756-9966-30-8721943236SinghSPPathuriGAschASRaoCVMadkaVStat3 inhibitors TTI-101 and SH5-07 suppress bladder cancer cell survival in 3D tumor modelsCells131463202410.3390/cells1317146339273033ShabanNZHegazyWAAbu-SerieMMTalaatIMAwadOMHabashyNHSeedless black Vitis vinifera polyphenols suppress hepatocellular carcinoma in vitro and in vivo by targeting apoptosis, cancer stem cells, and proliferationBiomed Pharmacother175116638202410.1016/j.biopha.2024.11663838688169ThinnesFPNeuroendocrine differentiation of LNCaP cells suggests: VDAC in the cell membrane is involved in the extrinsic apoptotic pathwayMol Genet Metab97241243200910.1016/j.ymgme.2009.04.01019487148Conti NibaliSDe SierviSLuchinatEMagrìAMessinaABroccaLMantovaniSOlivieroBMondelliMUDe PintoVVDAC1-interacting molecules promote cell death in cancer organoids through mitochondrial-dependent metabolic interferenceiScience27109853202410.1016/j.isci.2024.10985338784007KulyarMFMoQYaoWLiYNawazSLoonKSAhmedAEAlsaeghAAAl SyaadKMAkhtarMModulation of apoptosis and Inflammasome activation in chondrocytes: Co-regulatory role of Chlorogenic acidCell Commun Signal222202410.1186/s12964-023-01377-w38169388Van OpdenboschNLamkanfiMCaspases in cell death, inflammation, and diseaseImmunity5013521364201910.1016/j.immuni.2019.05.02031216460SoengasMSAlarcónRMYoshidaHGiacciaAJHakemRMakTWLoweSWApaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibitionScience284156159199910.1126/science.284.5411.15610102818PettigrewCACotterTGDeregulation of cell death (apoptosis): Implications for tumor developmentDiscov Med86163200919788869CarneiroBAEl-DeiryWSTargeting apoptosis in cancer therapyNat Rev Clin Oncol17395417202010.1038/s41571-020-0341-y32203277PengHYuanXShiRWeiXRenSYanCDingYLinYFanDYangMPHII-7 inhibits cell growth and induces apoptosis in leukemia cell line K562 as well as its MDR-counterpart K562/A02 through producing reactive oxygen speciesEur J Pharmacol718459468201310.1016/j.ejphar.2013.07.03823911883LiuJLiuYLiHWeiCMaoALiuWPanGPolyphyllin D induces apoptosis and protective autophagy in breast cancer cells through JNK1-Bcl-2 pathwayJ Ethnopharmacol282114591202210.1016/j.jep.2021.11459134481873WangSYadavAKHanJYAhnKSJangBCAnti-Growth, Anti-angiogenic, and pro-apoptotic effects by CX-4945, an inhibitor of casein kinase 2, on HuCCT-1 human cholangiocarcinoma cells via control of caspase-9/3, DR-4, STAT-3/STAT-5, Mcl-1, eIF-2α, and HIF-1αInt J Mol Sci236353202210.3390/ijms2311635335683032TangZDingJXiaoXSalvianolic acid a induces apoptosis and inhibits the C-Met expression in hepatocellular carcinoma HepG2 cell lineChin J Mod Appl Pharm315375412014HanahanDWeinbergRAHallmarks of cancer: The next generationCell144646674201110.1016/j.cell.2011.02.01321376230SerontEPintoABouzinCBertrandLMachielsJPFeronOPTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activationBr J Cancer10915861592201310.1038/bjc.2013.50523989949SunBZhaoYYangSLiXLiNWangYHanQLiuXTuQZhengJZhangXCelecoxib as a potential treatment for hepatocellular carcinoma in populations exposed to high PFAS levelsJ Hazard Mater489137613202510.1016/j.jhazmat.2025.13761339955994LiJBianXZhangCChenYHuangSZhaoSLiYIdentifying prognostic biomarkers and immune interactions in ovarian cancer associated with perfluorooctanoic acid exposure: Insights from comparative toxicogenomics and molecular docking studiesEcotoxicol Environ Saf291117831202510.1016/j.ecoenv.2025.11783139955862HuMTaoPWangYZhuCMaYLiuXCaiHKnockdown of CCNB2 inhibits the tumorigenesis of gastric cancer by regulation of the PI3K/Akt pathwaySci Rep155703202510.1038/s41598-025-89948-439962178NoorolyaiSShajariNBaghbaniESadreddiniSBaradaranBThe relation between PI3K/AKT signalling pathway and cancerGene698120128201910.1016/j.gene.2019.02.07630849534BiLChenJYuanXJiangZChenWSalvianolic acid A positively regulates PTEN protein level and inhibits growth of A549 lung cancer cellsBiomed Rep1213217201310.3892/br.2012.3324648921WülfingPKerstingCTioJFischerRJWülfingCPorembaCDialloRBöckerWKieselLEndothelin-1-, endothelin-A-, and endothelin-B-receptor expression is correlated with vascular endothelial growth factor expression and angiogenesis in breast cancerClin Cancer Res1023932400200410.1158/1078-0432.CCR-03-011515073116ZhangQWangSYuYSunSZhangYZhangYYangWLiSQiaoYSalvianolic acid A, as a novel ETA receptor antagonist, shows inhibitory effects on tumor in vitroInt J Mol Sci171244201610.3390/ijms1708124427490540LengXKanHWuQLiCZhengYPengGInhibitory effect of Salvia miltiorrhiza extract and its active components on cervical intraepithelial neoplastic cellsMolecules271582202210.3390/molecules2705158235268683LiSFangJSiTLuYJiangLSalvianolic acid A inhibits the growth of diffuse large B-cell lymphoma through MAPK pathwaysExp Hematol946068.e2202110.1016/j.exphem.2020.11.00733278489LiHYLiYYanCHLiLNChenXGInhibition of tumor growth by S-3-1, a synthetic intermediate of salvianolic acid AJ Asian Nat Prod Res4271280200210.1080/102860202100004906912450255XuanZZhangYLiDWangKHuangPShiJPLXNB1/SEMA4D signals mediate interactions between malignant epithelial and immune cells to promote colorectal cancer liver metastasisJ Cell Mol Med28e70142202410.1111/jcmm.7014239443302XieSHanSGongJFengZSunYYaoHShiPBee venom prompts the inhibition of gefitinib on proliferation, migration, and invasion of non-small cell lung cancer cells via EGFR-mediated autophagyToxicon251108149202410.1016/j.toxicon.2024.10814939442568LiXSunYGuoJChengYLuWYangWWangLChengZSodium bicarbonate potentiates the antitumor effects of Olaparib in ovarian cancer via cGMP/PKG-mediated ROS scavenging and M1 macrophage transformationBiomed Pharmacother180117509202410.1016/j.biopha.2024.11750939442234GuptaGPMassaguéJCancer metastasis: Building a frameworkCell127679695200610.1016/j.cell.2006.11.00117110329LiuLMengTZhengXLiuYHaoRYanYChenSYouHXingJDongYTransgelin 2 promotes paclitaxel resistance, migration, and invasion of breast cancer by directly interacting with PTEN and activating PI3K/Akt/GSK-3β pathwayMol Cancer Ther1824572468201910.1158/1535-7163.MCT-19-026131488699FaresJFaresMYKhachfeHHSalhabHAFaresYMolecular principles of metastasis: A hallmark of cancer revisitedSignal Transduct Target Ther528202010.1038/s41392-020-0134-x32296047MrozikKMBlaschukOWCheongCMZannettinoACWVandykeKN-cadherin in cancer metastasis, its emerging role in haematological malignancies and potential as a therapeutic target in cancerBMC Cancer18939201810.1186/s12885-018-4845-030285678SaldanhaRHo ThanhMTKrishnanNHehnlyHPattesonAVimentin supports cell polarization by enhancing centrosome function and microtubule acetylationJ R Soc Interface2120230641202410.1098/rsif.2023.064138835244XypolitaMEGoolamMBikoffEKRobertsonEJMouldAWThe zinc-finger transcription factor Blimp1/Prdm1 is required for uterine remodelling and repair in the mouseNat Commun161220202510.1038/s41467-025-56511-839890816CurranSMurrayGIMatrix metalloproteinases: Molecular aspects of their roles in tumour invasion and metastasisEur J Cancer3616211630200010.1016/S0959-8049(00)00156-810959048TongZZhangYGuoPWangWChenQJinJLiuSYuCMoPZhangLHuangJSteroid receptor coactivator 1 promotes human hepatocellular carcinoma invasiveness through enhancing MMP-9J Cell Mol Med28e18171202410.1111/jcmm.1817138506084LiKLiDHafezBBekhitMMSJardanYABAlanaziFKTahaEIAudaSHRamzanFJamilMIdentifying and validating MMP family members (MMP2, MMP9, MMP12, and MMP16) as therapeutic targets and biomarkers in kidney renal clear cell carcinoma (KIRC)Oncol Res32737752202410.32604/or.2023.04292538560573GuoJSongZMumingAZhangHAwutECysteine protease inhibitor S promotes lymph node metastasis of esophageal cancer cells via VEGF-MAPK/ERK-MMP9/2 pathwayNaunyn Schmiedebergs Arch Pharmacol39760516059202410.1007/s00210-024-03014-w38386044ChuangCYHoYCLinCWYangWEYuYLTsaiMCYangSFSuSCSalvianolic acid A suppresses MMP-2 expression and restrains cancer cell invasion through ERK signaling in human nasopharyngeal carcinomaJ Ethnopharmacol252112601202010.1016/j.jep.2020.11260131981746StasiakPSopelJLipowiczJMRawłuszko-WieczorekAAKorbeckiJJanuchowskiRThe role of elacridar, a P-gp inhibitor, in the Re-sensitization of PAC-resistant ovarian cancer cell lines to cytotoxic drugs in 2D and 3D cell culture modelsInt J Mol Sci261124202510.3390/ijms2603112439940891NikolaouMPavlopoulouAGeorgakilasAGKyrodimosEThe challenge of drug resistance in cancer treatment: A current overviewClin Exp Metastasis35309318201810.1007/s10585-018-9903-029799080JinQRenQChangXYuHJinXLuXHeNWangGNeuropilin-1 predicts poor prognosis and promotes tumor metastasis through epithelial-mesenchymal transition in gastric cancerJ Cancer1236483659202110.7150/jca.5285133995640YaoSLiuXFengYLiYXiaoXHanYXiaSUnveiling the role of HGF/c-Met signaling in Non-small cell lung cancer tumor microenvironmentInt J Mol Sci259101202410.3390/ijms2516910139201787XuJLiuSYangXCaoSZhouYParacrine HGF promotes EMT and mediates the effects of PSC on chemoresistance by activating c-Met/PI3K/Akt signaling in pancreatic cancer in vitroLife Sci263118523202010.1016/j.lfs.2020.11852333039386ShaoZPanHTuSZhangJYanSShaoAHGF/c-Met Axis: The advanced development in digestive system cancerFront Cell Dev Biol8801202010.3389/fcell.2020.0080133195182BahramiAShahidsalesSKhazaeiMGhayour-MobarhanMMaftouhMHassanianSMAvanAC-Met as a potential target for the treatment of gastrointestinal cancer: Current status and future perspectivesJ Cell Physiol23226572673201710.1002/jcp.2579428075018PilottoSCarbogninLKarachaliouNMaPCRosellRTortoraGBriaETracking MET de-addiction in lung cancer: A road towards the oncogenic targetCancer Treat Rev60111201710.1016/j.ctrv.2017.08.00228843992WuJCWangCTHungHCWuWJWuDCChangMCSungPJChouYWWenZHTaiMHHeteronemin is a Novel c-Met/STAT3 inhibitor against advanced prostate cancer cellsProstate7614691483201610.1002/pros.2323027416770ZhangYXiaMJinKWangSWeiHFanCWuYLiXLiXLiGFunction of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunitiesMol Cancer1745201810.1186/s12943-018-0796-y29455668ChenFYBiLQianLGaoJJiangYCChenWPIdentification of multidrug resistance gene MDR1 associated microRNA of salvianolic acid A reversal in lung cancerZhongguo Zhong Yao Za Zhi41327932842016(In Chinese)28920383LiHChenJXuCPangLChengXAntitumor effect of salvianolic acid A and on its reversal of multidrug resisitance in A549/MTX tumorChin J Clin Pharmacol Ther2212442017YeTChenRZhouYZhangJZhangZWeiHXuYWangYZhangYSalvianolic acid A (Sal A) suppresses malignant progression of glioma and enhances temozolomide (TMZ) sensitivity via repressing transgelin-2 (TAGLN2) mediated phosphatidylinositol-3-kinase (PI3K)/protein kinase B (Akt) pathwayBioengineered131164611655202210.1080/21655979.2022.207096335505656ZhangBZhangYDangWXingBYuCGuoPPiJDengXQiDLiuZThe anti-tumor and renoprotection study of E-[c(RGDfK)(2)]/folic acid co-modified nanostructured lipid carrier loaded with doxorubicin hydrochloride/salvianolic acid AJ Nanobiotechnology20425202210.1186/s12951-022-01628-x36153589XueLOuyangWQiPZhuYQiXZhangXZhangXWangLCuiLKey mechanisms of angiogenesis in the infarct core: Association of macrophage infiltration with venogenesisMol Brain1812202510.1186/s13041-025-01182-139953545YuYanYuanERegulatory effect of N6-methyladenosine on tumor angiogenesisFront Immunol151453774202410.3389/fimmu.2024.145377439295872SayedZSKhattapMGMadkourMAYasenNSElbaryHAElsayedRAAbdelkawyDAWadanASOmarINafadyMHCirculating tumor cells clusters and their role in Breast cancer metastasis; a review of literatureDiscov Oncol1594202410.1007/s12672-024-00949-738557916LuganoRRamachandranMDimbergATumor angiogenesis: Causes, consequences, challenges and opportunitiesCell Mol Life Sci7717451770202010.1007/s00018-019-03351-731690961JinRNeufeldLMcGahaTLLinking macrophage metabolism to function in the tumor microenvironmentNat Cancer6239252202510.1038/s43018-025-00909-239962208BergersGBenjaminLETumorigenesis and the angiogenic switchNat Rev Cancer3401410200310.1038/nrc109312778130LimJXYongYKDewiFRPChanSYLimVNanoscale strategies: Doxorubicin resistance challenges and enhancing cancer therapy with advanced nanotechnological approachesDrug Deliv Transl ResFebruary152025(Epub ahead of print)10.1007/s13346-025-01790-3QianCZhouYZhangTDongGSongMTangYWeiZYuSShenQChenWTargeting PKM2 signaling cascade with salvianic acid A normalizes tumor blood vessels to facilitate chemotherapeutic drug deliveryActa Pharm Sin B1420772096202410.1016/j.apsb.2024.02.00338799619KaurTWeadickBMaceTADesaiKOdomHGovindarajanRNucleoside transporters and immunosuppressive adenosine signaling in the tumor microenvironment: Potential therapeutic opportunitiesPharmacol Ther240108300202210.1016/j.pharmthera.2022.10830036283452TangCJiangSTLiCXJiaXFYangWLThe Effect of salvianolic acid a on Tumor-associated macrophage polarization and its mechanisms in the tumor microenvironment of Triple-negative breast cancerMolecules291469202410.3390/molecules2907146938611749NanYWuXLuoQChangWZhaoPZhangLLiuZOTUB2 silencing promotes ovarian cancer via mitochondrial metabolic reprogramming and can be synthetically targeted by CA9 inhibitionProc Natl Acad Sci USA121e2315348121202410.1073/pnas.231534812138701117LiuXZhaoJLiuFXieZLeiXWangZYangZZhouYTangGA Smart CA IX-targeting and pH-responsive nano-mixed micelles for delivery of FB15 with superior anti-breast cancer efficacyInt J Nanomedicine191024710262202410.2147/IJN.S45904739403708ZhangCPanYCaiRGuoSZhangXXueYWangJHuangJWangJGuYZhangZSalvianolic acid A increases the accumulation of doxorubicin in brain tumors through Caveolae endocytosisNeuropharmacology167107980202010.1016/j.neuropharm.2020.10798032014448QiuCZhangJZWuBXuCCPangHHTuQCLuYQGuoQYXiaFWangJGAdvanced application of nanotechnology in active constituents of Traditional Chinese MedicinesJ Nanobiotechnology21456202310.1186/s12951-023-02165-x38017573LuLZhangHQianYYuanYIsolation of salvianolic acid A, a minor phenolic carboxylic acid of Salvia miltiorrhizaNat Prod Commun5805808201020521551YangMYLiuYYuYWGongBFRuanJFanHYApplication of targeted liposomes-based salvianolic acid A for the treatment of ischemic strokeNeurotherapeutics21e00342202410.1016/j.neurot.2024.e0034238493057
Chemical structure of salvianolic acid A (PubChem CID: 5281793).
Antitumor effects of salvianolic acid A. SAA exerts antitumor effects through multiple mechanisms, including the regulation of intracellular energy dynamics (e.g., induction of endogenous apoptosis and suppression of mitochondrial membrane potential), inhibition of tumour cell proliferation, suppression of tumour cell migration and invasion, enhancement of chemotherapy sensitivity and reversal of chemotherapy resistance, inhibition of tumour angiogenesis and modulation of genomic instability and mutations. SAA, salvianolic acid A.
Schematic diagram of the membrane, cytoplasmic and nuclear targets of salvianolic acid A. Akt (PKB), protein kinase B; Apaf-1, apoptotic protease activating factor 1; ATM, Ataxia-telangiectasia mutated; ATR, Ataxia telangiectasia and Rad3-related protein; Bad, Bcl-2 associated agonist of cell death; Bak, Bcl-2 homologous antagonist/killer; Bax, Bcl-2-associated X protein; Bcl-2, B-cell lymphoma-2; Bcl-xl, B-cell lymphoma extra large; BID, Bcl-2 homology 3 interacting domain death agonist; c-MET, cellular-mesenchymal epithelial transition factor; Raf, serine/threonine kinase; Caspase-3/8/9/10, cysteinyl aspartate specific proteinase; CDK4/6, cyclin-dependent kinase 4/6; Chk 2, checkpoint kinase-2; Cyto C, cytochrome C; ERK1/2, extracellular-signal-regulated kinase 1/2; GSH, glutathione; Ki67, marker of proliferation Ki-67; MDR1, multidrug resistance-1; MEK, MAPK kinase; MMP2, matrix metallopeptidase 2; mTOR, mammalian target of rapamycin; mTOR C1, mechanistic target of rapamycin complex 1; p-, phosphorylated; p90R SK, the 90 kDa ribosomal s6 kinases; p70S6K, 70 kDa ribosomal protein S6 kinase; PDK1, pyruvate dehydrogenase kinase 1; P-gp, P-glycoprotein; PI3K, phosphoinositide 3-kinase; PTEN, phosphatase and tensin homolog; ROS, reactive oxygen species; Ras, rat sarcoma; SAA, salvianolic acid A; Src, steroid receptor coactivator; TAGLN2, transgelin 2; 4EBP1, eIF4E-binding protein.